

EBP Phase 1: Dylan Wilson, Taylor Fox, Kennedy Cantelli

1) Title of Poster:

- Monitor Risk Using Poke and Sticks
- “2 Bleed or Not 2 Bleed”
- Diabetes: Don’t Sugarcoat it

2) Reference (APA Format):

Martens T, Beck RW, Bailey R, Ruedy KJ, Calhoun P, Peters AL, Pop-Busui R, Philis-Tsimikas A, Bao S, Umpierrez G, Davis G, Kruger D, Bhargava A, Young L, McGill JB, Aleppo G, Nguyen QT, Orozco I, Biggs W, Lucas KJ, Polonsky WH, Buse JB, Price D, Bergenstal RM; MOBILE Study Group. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial. *JAMA*. 2021 Jun 8;325(22):2262-2272. doi: 10.1001/jama.2021.7444. PMID: 34077499; PMCID: PMC8173473.

3) Question: What was the needed Hb1ac needed to participate in the trial?

A) 5.7 to 6.4%

B) $\leq 5.6\%$

C) 7.8 to 11.5%

D) $\geq 11.5\%$

Answer: C: The Hb1ac needed to participate was 7.8% to 11.5%.

4) Attach Full Article

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173473/>

Answer Highlighted on PDF attached separately on EBP Phase 1 Drop Box since our PDF would not attach to our google doc. We turned it in separately.

